• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    OEMs Seek Molders Offering Timely Techniques

    Robotic Surgery: Cutting Through to the Latest

    Packaging, Sterilization Considerations Go Part and Parcel with Product Development

    Cybersecurity Challenges Leave Medical Device Makers Insecure

    OEMs Are Demanding Designs that Challenge Suppliers
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Regulatory
    Financial/Business
    Top News
    ENDRA Life Sciences Issued 27th Patent

    AI-Enabled SKOUT Device Improves Colorectal Cancer Screening

    Simon Johnson Appointed as Senior Business Development VP at MedAcuity

    Foster Corporation Named Marketing Partner for AdvanSource Biomaterials

    Researchers Develop New Apparatus for the Treatment of Cardiovascular Diseases
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    OEMs Seek Molders Offering Timely Techniques

    Robotic Surgery: Cutting Through to the Latest

    Packaging, Sterilization Considerations Go Part and Parcel with Product Development

    Cybersecurity Challenges Leave Medical Device Makers Insecure

    OEMs Are Demanding Designs that Challenge Suppliers
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    Theranos Fraud Trial, Part II: The Blame Game Continues

    An Update on Surgical Robotics

    Letting the Light In: How Failure Analysis is the Cornerstone of Success

    Three Talent Strategies to Attract High-Demand Skills

    The Advantages of Bioburden Screening for Sterilization Validation
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    Fusion Biotec Inc.

    JBC Technologies

    Xact Wire EDM Corp.

    BMP Medical

    Trademark Plastics Inc.
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    ‘Right to Repair’: Separating Fact from Fiction

    Taking a Holistic Approach to Decentralized Clinical Trials (DCTs)

    Investment in Health Startups Drops

    The Power of Leveraging Customer Relationships

    Cost Effective & Efficient Wire EDM Techniques
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    Fusion Biotec Inc.

    JBC Technologies

    Xact Wire EDM Corp.

    BMP Medical

    Trademark Plastics Inc.
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • eBook
    • Resources
    • Podcasts
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Breaking News

    Exact Sciences to Acquire Genomic Health for $2.8B

    The combined company will offer two of the strongest and fastest-growing brands in cancer diagnostics, Cologuard and Oncotype DX.

    Exact Sciences to Acquire Genomic Health for $2.8B
    Related CONTENT
    • Diagnostic May Bring Faster, Cheaper Cancer Testing to Remote Settings
    • Application Detects Cancer Cells in Abdominal Cavity in Real Time
    • New AI 'Smart Pill' Images Gut to Spot Cancer
    • Blood Test May Help Doctors Catch Pancreatic Cancer Early
    • FDA Grants Lucid Diagnostics Breakthrough Device Designation for Esophageal DNA Test
    Exact Sciences07.29.19
    Exact Sciences Corp. and Genomic Health Inc. have entered into a definitive agreement under which Exact Sciences will combine with Genomic Health for $72.00 per share in a cash and stock transaction valued at $2.8 billion. The transaction, which has been unanimously approved by the Boards of Directors of both companies, is expected to be completed by the end of 2019.
     
    Together, Exact Sciences and Genomic Health will create a leading global cancer diagnostics company. The combined company will offer two of the strongest and fastest growing brands in cancer diagnostics, Cologuard and Oncotype DX, providing a robust platform for continued growth. With this enhanced platform, including a commercial presence in more than 90 countries, the combined company expects to continue to increase adoption of current tests, and to bring new innovative cancer diagnostics to patients throughout the world.
     
    On a pro forma basis, the combined company expects to generate revenue of approximately $1.6 billion and gross profit of approximately $1.2 billion in 2020. Additionally, the combination is expected to generate annualized cost synergies of approximately $25 million within the third full year following close, primarily through reducing public company costs and purchasing optimization.
     
    "Uniting the best minds and molecular diagnostics capabilities will advance the fight against cancer. Combining industry pioneers Exact Sciences and Genomic Health is a pivotal step toward building the leading cancer diagnostics company in the world," said Kevin Conroy, chairman and CEO of Exact Sciences. "Exact Sciences is continuing to grow sales and expand adoption of Cologuard at a rapid pace, and Genomic Health's Oncotype DX is the global standard of care to inform treatment decisions for women with breast cancer. Together, with our collective resources and broader platform, we will be able to provide our existing tests to more people, while also accelerating the development and launch of future cancer diagnostic tests. We are excited to join together two teams who are united in their dedication to making a positive impact on patients' lives."
     
    "We are very pleased to join forces with Exact Sciences, a company and team with which we have a shared vision to revolutionize the way cancer is diagnosed and treated," said Kim Popovits, chairman of the board, chief executive officer and president of Genomic Health. "Genomic Health has achieved incredible success over nearly two decades in pioneering cancer diagnostics, and the recent landmark TAILORx trial results set a new standard of care for the use of the Oncotype DX test for women with early-stage invasive breast cancer. This transaction provides immediate value to Genomic Health stockholders through an upfront cash payment, as well as ownership in a combined company with enhanced financial strength and the commercial and R&D capabilities to continue to drive significant growth into the future."
     
    Cologuard and Oncotype DX, the companies' leading brands, will respectively continue to help detect colorectal cancer and inform treatment decisions in colorectal, breast and prostate cancer, which collectively represent approximately 40 percent of all solid tumor incidence.
     
    Exact Sciences' Cologuard has a total available U.S. screening market of $15 billion, with an additional potential $3 billion opportunity among people ages 45-491. To date, Cologuard has captured less than 6 percent of the large addressable market of people over 50 years old, and is rapidly building on its 174,000-healthcare provider customer base, with a goal of reaching 40 percent share of the market over the long-term. In the second quarter of 2019, Cologuard revenue grew 94 percent year-over-year.   
     
    Genomic Health's Oncotype IQ portfolio has guided personalized treatment decisions for more than one million cancer patients worldwide, and delivered more than 19 percent year-over-year overall revenue growth in the second quarter of 2019. Genomic Health estimates that its Oncotype DX suite of products in oncology and urology have a total available market of $2 billion.

    The transaction will create a combined R&D team with extensive clinical capabilities and a robust evidence generation engine, complemented by proven regulatory expertise, and key relationships with oncologists. The combined commercial organization will have more than 1,000 team members inclusive of sales, marketing and reimbursement teams. The combined company will have the financial strength to support a high level of investment in R&D. This will support the development of innovative products across the diagnostic paradigm, including the ongoing work to identify proprietary biomarkers across the world's 15 deadliest cancers, while continuing to advance the adoption of current products.  

    The combined company will have a commercial presence in more than 90 countries and expanded reach across primary care, oncology, OB/GYN, gastroenterology, and urology to support growth of existing and future cancer tests. The combined company will build upon Genomic Health's presence in the San Francisco Bay Area, providing lab infrastructure in a state where the Medicare Administrative Contractor participates in the MolDx program, which may facilitate reimbursement of future liquid biopsy products.
     
    Under the terms of the agreement, for each share of Genomic Health common stock they own, Genomic Health stockholders will receive $27.50 in cash and $44.50 in shares of Exact Sciences stock, subject to a 10 percent collar centered on Exact Sciences' volume-weighted average price for the 45 trading days ended July 26, 2019.
     
    Based on the parties' closing stock prices as of July 26, 2019, the last trading day prior to today's announcement, the total per-share consideration represents a premium of approximately 19 percent to Genomic Health's volume-weighted average price ("VWAP") for the last 30 trading days. Upon closing, Exact Sciences shareholders are expected to own approximately 91 percent of the combined company, and Genomic Health stockholders are expected to own approximately 9 percent.
     
    The transaction is subject to customary closing conditions and regulatory approvals, including the approval of stockholders of Genomic Health. Felix and Julian Baker and certain funds advised by entities with whom they are affiliated, which collectively own approximately 25.3 percent of the outstanding shares of Genomic Health common stock, have entered into agreements to vote in favor of the transaction.
     
    Centerview Partners and XMS Capital Partners are serving as financial advisors to Exact Sciences and Skadden, Arps, Slate, Meagher & Flom LLP is serving as legal advisor. Goldman Sachs & Co. LLC is serving as financial advisor to Genomic Health and Sullivan & Cromwell LLP and Pillsbury Winthrop Shaw Pittman LLP are serving as legal advisors.
    Related Searches
    • exact sciences
    • breast cancer
    • development
    • sales
    Related Knowledge Center
    • Diagnostics
    Suggested For You
    Diagnostic May Bring Faster, Cheaper Cancer Testing to Remote Settings Diagnostic May Bring Faster, Cheaper Cancer Testing to Remote Settings
    Application Detects Cancer Cells in Abdominal Cavity in Real Time Application Detects Cancer Cells in Abdominal Cavity in Real Time
    New AI New AI 'Smart Pill' Images Gut to Spot Cancer
    Blood Test May Help Doctors Catch Pancreatic Cancer Early Blood Test May Help Doctors Catch Pancreatic Cancer Early
    FDA Grants Lucid Diagnostics Breakthrough Device Designation for Esophageal DNA Test FDA Grants Lucid Diagnostics Breakthrough Device Designation for Esophageal DNA Test
    3. GE Healthcare 3. GE Healthcare
    AI Tool Identifies Cancer Outcomes Using Radiology Reports AI Tool Identifies Cancer Outcomes Using Radiology Reports
    COSTAS Inc. Acquires Medical Nanotechnology Company COSTAS Inc. Acquires Medical Nanotechnology Company
    Portable Device Tests If Targeted Chemo Is Working Portable Device Tests If Targeted Chemo Is Working
    Hillrom Sells Surgical Consumables Business to Audax for $170M Hillrom Sells Surgical Consumables Business to Audax for $170M
    Boston Scientific Sells Microspheres to Varian Boston Scientific Sells Microspheres to Varian
    Glaukos Corporation to Acquire DOSE Medical Corporation Glaukos Corporation to Acquire DOSE Medical Corporation
    Graphene & Tiny Droplets Spot Stomach-Cancer Causing Bacteria Graphene & Tiny Droplets Spot Stomach-Cancer Causing Bacteria
    Misonix Acquires Solsys Medical for $97 Million Misonix Acquires Solsys Medical for $97 Million
    ZOLL Buys Cardiac Science Corp. to Boost AED Portfolio ZOLL Buys Cardiac Science Corp. to Boost AED Portfolio

    Related Breaking News

    • Chronic Disease | Diagnostics
      Diagnostic May Bring Faster, Cheaper Cancer Testing to Remote Settings

      Diagnostic May Bring Faster, Cheaper Cancer Testing to Remote Settings

      The CytoPAN is used to study breast cells gathered with fine-needle aspiration, a less invasive alternative to standard biopsies.
      American Association for the Advancement of Science 08.07.20

    • Chronic Disease | Diagnostics
      Application Detects Cancer Cells in Abdominal Cavity in Real Time

      Application Detects Cancer Cells in Abdominal Cavity in Real Time

      New approach from Tel Aviv University combines medicine, engineering, and computer science.
      American Friends of Tel Aviv University 07.23.20

    • Diagnostics
      New AI

      New AI 'Smart Pill' Images Gut to Spot Cancer

      Now in prototype development, SmartCap is a new generation diagnostic tool.
      University of Saskatchewan 07.09.20


    • Diagnostics
      Blood Test May Help Doctors Catch Pancreatic Cancer Early

      Blood Test May Help Doctors Catch Pancreatic Cancer Early

      Penn study shows liquid biopsy may be viable option for both diagnosis and disease staging.
      Penn Medicine 04.16.20

    • FDA Grants Lucid Diagnostics Breakthrough Device Designation for Esophageal DNA Test

      FDA Grants Lucid Diagnostics Breakthrough Device Designation for Esophageal DNA Test

      Test is designed to facilitate the diagnosis of Barrett’s Esophagus, with and without dysplasia.
      Globe Newswire 03.30.20

    Loading, Please Wait..

    Trending
    • Siemens Healthineers & The Ohio State University Wexner Medical Center Enter Strategic Partnership
    • 5 Ways Plastics Revolutionized The Healthcare Industry
    • How To Overcome The Top 6 Medical Device Manufacturing Challenges
    • ‘Right To Repair’: Separating Fact From Fiction
    • The Future Of Biomedical Engineering Advancements
    Breaking News
    • ENDRA Life Sciences Issued 27th Patent
    • AI-Enabled SKOUT Device Improves Colorectal Cancer Screening
    • Simon Johnson Appointed as Senior Business Development VP at MedAcuity
    • Foster Corporation Named Marketing Partner for AdvanSource Biomaterials
    • Researchers Develop New Apparatus for the Treatment of Cardiovascular Diseases
    View Breaking News >
    CURRENT ISSUE

    June 2022

    • OEMs Seek Molders Offering Timely Techniques
    • Robotic Surgery: Cutting Through to the Latest
    • Packaging, Sterilization Considerations Go Part and Parcel with Product Development
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Pharmavite Expands in Ohio with $200 Million Investment
    Nestlé Health Science Expands in New Zealand with Deal to Buy The Better Health Company
    Younger Consumers Drive Growing Demand for Ingestible Beauty and Skin Care Products
    Coatings World

    Latest Breaking News From Coatings World

    Clariant’s Launches Dispersogen Flex 100
    Lincoln Tech Enters Partnership with AkzoNobel
    AkzoNobel Launches International Interzone 945GF
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    ENDRA Life Sciences Issued 27th Patent
    AI-Enabled SKOUT Device Improves Colorectal Cancer Screening
    Simon Johnson Appointed as Senior Business Development VP at MedAcuity
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Takeda to Expand U.S. Footprint
    Croda Pharma's Lipid Systems Capability to Support mRNA Vaccines
    WuXi STA Opens High-Potency API Plant
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Latest Updates About Cosmoprof North America
    Meet the Clean Beauty Brand for Dogs
    Paco Rabanne Introduces Elle Fanning as Ambassador for New ‘Fame’ Fragrance
    Happi

    Latest Breaking News From Happi

    Two-Part Skincare Product Patented by Estée Lauder Companies
    American Cleaning Institute Pens Letter to Congress Encouraging Examination of Recyclability Improvements
    The Expert Panel for Fragrance Safety Celebrates 55 Years
    Ink World

    Latest Breaking News From Ink World

    INX Launches INXFlex Contour for Shrink Sleeve Market
    Xerox Announces Unexpected Passing of Vice Chairman and CEO John Visentin
    MNYPIA Golf Outing Set to Tee Off on Aug. 17
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Meyers purchased by third generation of Dillon family
    Epson now shipping ColorWorks C4000 inkjet label printer
    Nobelus launches new films for prime labels
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    What You’re Reading on Nonwovens-Industry.com
    Daio, Livedo Partner to Recycle Diapers
    Suominen Launches Hydraspun Reserve
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    3D Systems and EMS-GRILTECH Enter Strategic Partnership
    AIP Researchers Develop Microfluidic-Based Soft Robotic Prosthetic
    David Sharp Named Global Marketing VP at Catalyst OrthoScience
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Impinj Launches E910 RFID Reader Chip for Next Generation Enterprise IoT
    onsemi Receives Recognition for Sustainability for Third Straight Year
    Xerox Announces the Unexpected Passing of Vice Chairman and CEO John Visentin

    Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login